Therapies for Children With Autism Spectrum Disorders

Evidence Table. Therapies for children with ASD
Study
Inclusion/Exclusion
Description Intervention
Criteria/Population
to May 2000
NR
Funding: Co-interventions held Gender:
NR
stable during treatment: M, n (%): 16 (53.3)
Author industry
relationship
NR
F, n (%): 14 (46.7)
disclosures: Frequency of contact Race/ethnicity:
NR
during study: End of NR
Design: each 4 week diet phase
Prospective case and at the end of each 2 SES:
series
week diet-free phase Maternal education: NR
Evangeliou et al.,
2003 (continued)
Monthly Psychiatric
examination at the end of
the diet and every month
after discontinuation of
diet for 6 months
Concomitant therapies,
n (%):
Haloperidol: 30 (100)
N at enrollment:
G1: 30
N at follow-up:
G1: 30
Household income: NR
Diagnostic approach:
Referral
Diagnostic tool/method:
CARS
Diagnostic category, n
(%):
Autism : 30 (100)
Other characteristics:
NR
C-357
Baseline
Measures Outcomes
Improvement in
Pre-CARS: 8, 45.25 Social behavior,
± 2.76
interactions,
speech,
Elevated 3- stereotypy &
ohisovaleric acid: 3 learning, n (%): 18
(60)
Pathologic levels of
beta -
hydroxybutyrate
abnormal (1.05 -
1.45 mmol/L): 6
Elevated beta-
OHb following
diet, n (%): 4
(13.3)
Interrupted diet, n
(%): 5 (16.7)
Elevated beta-
OHb following
diet, n (%): 2 (6.7)
Improvement
significantly
(CARS > 12
units): 2
(CARS=16, 13
units)
Average (CARS >
8-12 units): 8
(CARS mean=7.1
units)
Minor (CARS 2-8
units): 8
(CARS mean =7.1
units)
Among 6 with the
pathologic levels
of beta -
hydroxybutyrate,
improvement , n:
Significant: 1
Average: 2
Minor: 1
(2 discontinued
the diet)
Harms:
NR
Modifiers:
NR